Evaluation of drug-drug interactions between anticoagulants and antiplatelet agents in cardiovascular patients

Abstract

This paper evaluates the prevalence and clinical implications of interactions between anticoagulants and antiplatelet agents in cardiovascular patients. In the study, the case used was 300 patients, and the objective was to identify drug-drug interactions and the associated risks through a retrospective analysis of the patient’s records. The research revealed that 50% of the patients had DDIs and the most common one was ASA- Warfarin followed by Clopidogrel- Dabigatran. The interaction group had a higher rate of major bleeding complications at 20% as opposed to the non-interaction group which had a 3% rate. 3%. Also, minor bleeding events and hospitalizations were significantly higher in patients with interactions. Such outcomes prove the possibility of the adverse effect of the simultaneous use of these drugs and the importance of close monitoring and individual approach to the patient. This paper emphasizes the need to enhance the clinical practice guidelines and decision support tools to minimize harm to patients. More studies should be conducted with more patients of different ages and genders and the long-term effects of such interactions.